Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP

European Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2010, Pages 1304-1313

  Jia, Yan ^a   Chiu, Ting Lan ^b   Amin, Elizabeth A ^b   Polunovsky, Vitaly ^c   Bitterman, Peter B ^c   Wagner, Carston R ^a,b  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anticancer; Antifibrotic; CoMFA; CoMSIA; eIF4E; Translation initiation

Indexed keywords

[5 (2 AMINO 7 BENZYL 6 OXO 1H PURIN 1 IUM 9(6H) YL) 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 6 OXO 7 [3 (TRIFLUOROMETHYL)BENZYL] 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (2 CHLORO 5 FLUOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (2 CHLOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (2 FLUOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (2 METHYLBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (2,5 DICHLOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (3 CHLOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (3 FLUOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (3 METHOXYBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (3 METHYLBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (3 NITROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (4 CARBOXYBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (4 CHLOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (4 FLUOROBENZYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; [5 [2 AMINO 7 (NAPHTHALEN 2 YLMETHYL) 6 OXO 1H PURIN 1 IUM 9(6H) YL] 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL]METHYLPHOSPHATE; GUANOSINE DERIVATIVE; INITIATION FACTOR 4E; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

5'-GUANYLIC ACID; AMINO ACID SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EUKARYOTIC INITIATION FACTOR-4E; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; RNA CAPS;

EID: 77349115916     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.11.054     Document Type: Article

References (40)

1. Li B.D.L., Liu L., Dawson M., and Benedetti A.D. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast Carcinoma. Cancer 79 (1997) 2385-2390
2. Gingrast N.S.a.A.-C. The mRNA 5′ cap-binding protein elF4E and control of cell growth. Curr. Opin. Cell Biol. 10 (1998) 268-275
3. Benedetti A.D., and Harris A.L. eIF4E Expression in tumors: its possible role in progresstion of malignancies. Int. J. Biochem. Cell Biol. 31 (1999) 59-72
4. v.d. Haar T., Gross J.D., Wagner G., and McCarthy J.E.G. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat. Struct. Mol. Biol. 11 (2004) 503-511
5. Avdulov S., Li S., Michalek V., Burrichter D., Peterson M., Perlman D.M., Manivel J.C., Sonenberg N., Yee D., Bitterman P.B., and Polunovsky V.A. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5 (2004) 553-563
6. Watkins S.J., and Norbury C.J. Translation initiation and its deregulation during tumorigenesis. Br. J. Cancer 86 (2002) 1023-1027
7. Nathan C.-A.O., Liu L., Li B.D., Abreo F.W., Nandy I., and De Benedetti A. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 15 (1995) 579-584
8. Clemens M.J., and Bommer U.-A. Translational control: the cancer connection. Int. J. Biochem. Cell Biol. 31 (1999) 1-23
9. Miyagi Y., Sugiyama A., Asai A., Okazaki T., Kuchino Y., and Kerr S.J. Elevated levels of eukaryotic translation initiation factor eIF-4E, mRNA in a broad spectrum of transformed cell lines. Cancer Lett. 91 (1995) 247-252
10. Scott P.A.E., Smith K., Poulsom R., Benedetti A.D., Bicknell R., and Harris A.L. Differential expression of vascular endothelial growth factor mRNA vs. protein isoform expression in human breast cancer and relationship to eIF-4E, Br. J. Cancer 77 (1998) 2120-2128
11. DeFatta R.J., Turbat-Herrera E.A., Li B.D., Anderson W., and Benedetti A.D. Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia. Int. J. Cancer 80 (1999) 516-522
12. Joshi B., Cai A.-L., Keiper B.D., Minich W.B., Mendez R., Beach C.M., Stepinski J., Stolarski R., Darzynkiewicz E., and Rhoads R.E. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J. Biol. Chem. 270 (1995) 14597-14603
13. Zuberek J., Wyslouch-Cieszynska A., Niedzwiecka A., Dadlez M., Stepinski J., Augustyniak W., Gingras A.-C., Zhang Z., Burley S.K., Sonenberg N., Stolarski R., and Darzynkiewicz E. Phosphorylation of eIF4E attenuates its interaction with mRNA 5′ cap analogs by electrostatic repulsion: intein-mediated protein ligation strategy to obtain phosphorylated protein. RNA 9 (2003) 52-61
14. Rousseau D., Gingras A.C., Pause A., and Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13 (1996) 2415-2420
15. Niedzwiecka A., Marcotrigiano J., Stepinski J., Jankowska-Anyszka M., Wyslouch-Cieszynska A., Dadlez M., Gingras A.-C., Mak P., Darzynkiewicz E., Sonenberg N., Burley S.K., and Stolarski1 R. Biophysical studies of eif4e cap-binding protein: recognition of mRNA 50 cap structure and synthetic fragments of eif4g and 4e-bp1 proteins. J. Mol. Biol. 319 (2002) 615-635
16. Poulin F., Gingras A.-C., Olsen H., Chevalier S., and Sonenberg N. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J. Biol. Chem. (1998) 14002-14007
17. Richter J.D., and Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433 (2005) 477-480
18. Duncan R., Milburn S.C., and Hershey J.W.B. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J. Biol. Chem. 262 (1987) 380-388
19. Darzynkiewicz E., Stepinski J., Ekiel I., Goyer C., Sonenberg N., Temeriusz A., Jin Y., Sijuwade T., Haber D., and Tahara S.M. Inhibition of eukaryotic translation by nucleoside 5′-monophosphate analogues of mRNA 5′-Cap: changes in N7 substituent affect analogue activity. Biochemistry 28 (1989) 4771-4778
20. Ghosh B., Benyumov A.O., Ghosh P., Jia Y., Avdulov S., Dahlberg P.S., Peterson M., Smith K., Polunovsky V.A., Bitterman P.B., and Wagner C.R. Non-toxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem. Biol. 4 (2009) 367-377
21. Brown C.J., McNae I., Fischer P.M., and Walkinshaw M.D. Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivatives. J. Mol. Biol. 372 (2007) 7-15
22. Cramer R.D., Patterson D.E., and Bruce J.D. Comparative molecular field analysis (CoMFA). 1. Effects of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
23. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37 (1994) 4130-4146
24. Eldridge M.D., Murray C.W., Auton T.R., Paolini G.V., and Mee R.V. Empirical scoring functions: I. the development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des 11 (1997) 425-445
25. Ghosh P., Cheng J., Chou T.-F., Jia Y., Avdulov S., Bitterman P.B., Polunovsky V.A., and Wagner C.R. Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expr. Purif. 60 (2008) 132-139
26. Niedzwiecka A., Stepinski J., Antosiewicz J.M., Darzynkiewicz E., and Stolarski R. Biophysical approach to studies of cap-eIF4E interaction by synthetic cap analogs. Meth. Enzymol. 430 (2007) 209-245
27. T.I. SYBYL 7.1, 1699 South Hanley Rd., St. Louis, Missouri, 63144, (USA).
28. Amin E.A., and Welsh W.J. Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) Inhibitors: applying a "divide and conquer" strategy. J. Med. Chem. 44 (2001) 3849-3855
29. Amin E.A., and Welsh W.J. Highly predictive CoMFA and CoMSIA models for two series of stromelysin-1 (MMP-3) inhibitors elucidate S1′ and S1-S2′ binding modes. J. Chem. Inf. Model. 46 (2006) 1775-1783
30. Ghosh P., Park C., Peterson M.S., Bitterman P.B., Polunovsky V.A., and Wagner C.R. Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. Bioorg. Med. Chem. Lett. 15 (2005) 2177-2180
31. Gross J.D., Moerke N.J., Haar T.v.d., Lugovskoy A.A., Sachs A.B., McCarthy J.E.G., and Wagner G. Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E. Cell 115 (2003) 739-750
32. Haar T.v.d., Oku Y., Ptushkina M., Moerke N., Wagner G., Gross J.D., and McCarthy J.E.G. Folding transitions during assembly of the eukaryotic mRNA cap-binding complex. J. Mol. Biol. 356 (2006) 982-992
33. Slepenkov S.V., Darzynkiewicz E., and Rhoads R.E. Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides. J. Biol. Chem. 281 (2006) 14927-14938
34. 7GpppG•eIF4E•eIF4G complex. J. Biol. Chem. 283 (2008) 25227-25237
35. Mittal R.R., Harris L., McKinnon R.A., and Sorich M.J. Partial charge calculation method affects CoMFA QSAR prediction accuracy. J. Chem. Inf. Model. 49 (2009) 704-709
36. Graff J.R., Konicek B.W., Carter J.H., and Marcusson E.G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68 (2008) 631-634
37. Moerke N.J., Aktas H., Chen H., Cantel S., Reibarkh M.Y., Fahmy A., Gross J.D., Degterev A., Yuan J., Chorev M., Halperin J.A., and Wagner G. Small molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128 (2007) 257-267
38. Darzynkiewicz E., Ekiel I., Lassota P., and Tahara S.M. Inhibition of eurkaryotic translation by analogues of messenger RNA 5′-cap: chemical and biological consequences of 5′-phosphate modifications of 7-methylguanosine 5′-monophosphate. Biochemistry 26 (1987) 4372-4380
39. Zeng J. Mini-review: computational structure-based design of inhibitors that target protein surfaces. Comb. Chem. High Throughput Screen. 3 (2000) 355-362
40. Rutkowska-Wlodarczyk I., Janusz Stepinski M.D., Darzynkiewicz E., Stolarski R., and Niedzwiecka A. Structural changes of eIF4E upon binding to the mRNA 5′ monomethylguanosine and trimethylguanosine cap. Biochemistry 47 (2008) 2710-2720